Cover Image

Targeted Agents

Deepak Sundriyal, Meenu Walia

Keywords


Targeted therapy; quality of life; monoclonal antibodies

Full Text:

PDF

References


Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987, 69:584-591

Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989, 9:1165-1172

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353:1673-1684

Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of Imatinib therapy: a single institution historical experience. Blood. 2012, 119:1981-1987

Fojo T, Parkinson DR. Biologicaly targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res. 2010, 16:5972-5980

Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J med. 2011. 364:2060-2065


Refbacks

  • There are currently no refbacks.


AJCC-REP (ISSN 2572-5742)Copyright © 2012-2020. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States